Key result
Only 7.8% of patients with apparently resistant hypertension ultimately received a baroreflex activation therapy system, primarily due to achieving blood pressure control by drug adjustment or identifying secondary hypertension.
Why the study?
Uncontrolled hypertension is a main cardiovascular risk factor and baroreflex activation therapy (BAT) effectively addresses true resistant hypertension, but patient eligibility in a staged assessment and medication adherence needed evaluation.
What are the rates and primary reasons for non-eligibility for baroreflex activation therapy in patients with apparently resistant hypertension?
Cohort (n=345)
No
What are the rates and primary reasons for non-eligibility for baroreflex activation therapy in patients with apparently resistant hypertension?
A structured clinical assessment of apparently resistant hypertension reveals that most patients can achieve blood pressure control through drug adjustment or treatment of secondary causes, limiting the necessity for device-based therapies like BAT.
Answers are grounded in this paper and cite their sources.
Structured assessment of apparently resistant hypertension often limits BAT eligibility; leaves open the need for prospective trials of device therapy in optimized patients.
Uncontrolled hypertension is a main risk factor for cardiovascular morbidity. Baroreflex activation therapy (BAT) is an effective therapy option addressing true resistant hypertension. We evaluated patients' eligibility for BAT in a staged assessment as well as adherence to antihypertensive drug therapy. Therefore, we analyzed files of 345 patients, attending the hypertension clinic at University Medicine Göttingen. Additionally, gas chromatographic-mass spectrometric urine analyses of selected individuals were performed evaluating their adherence. Most common cause for a revoked BAT recommendation was blood pressure (BP) control by drug adjustment (54.2%). Second leading cause was presence of secondary hypertension (31.6%). Patients to whom BAT was recommended (59 (17.1%)) were significantly more often male (67.8% vs. 43.3%, P = .0063), had a higher body mass index (31.8 ± 5.8 vs. 30.0 ± 5.7 kg/m², P = .0436), a higher systolic office (168.7 ± 24.7 vs. 147.7 ± 24.1 mmHg, P < .0001), and 24h ambulatory BP (155.0 ± 14.6 vs. 144.4 ± 16.8 mmHg, P = .0031), took more antihypertensive drugs (5.8 ± 1.3 vs. 4.4 ± 1.4, P < .0001), and suffered more often from numerous concomitant diseases. Eventually, 27 (7.8%) received a BAT system. In the toxicological analysis of 75 patients, mean adherence was 75.1%. 16 patients (21.3%) showed non-adherence. Thus, only a small number of patients eventually received a BAT system, as treatable reasons for apparently resistant hypertension could be identified frequently. This study is-to our knowledge-the first report of a staged assessment of patients' suitability for BAT and underlines the need for a careful examination and indication. Non-adherence was proven to be a relevant issue concerning apparently resistant hypertension and therefore non-eligibility for interventional antihypertensive therapy.
No takes yet. Share an insight, caveat, or question.
Schäfer et al. (2021) conducted a cohort in Apparently resistant hypertension (n=345). Staged assessment for baroreflex activation therapy eligibility was evaluated on Proportion of patients receiving a BAT system and primary reasons for revoked recommendation. Only 7.8% of patients with apparently resistant hypertension ultimately received a baroreflex activation therapy system, primarily due to achieving blood pressure control by drug adjustment or identifying secondary hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: